Leeds based Surfachem has consolidated its reputation as one of the leaders in the specialty chemical distribution sector and has recently gained registration by the Medicines and Healthcare Regulatory Authority (MHRA) for the import and distribution of Active Pharmaceutical Ingredients (APIs).
The latest approval means that Surfachem fulfils the mandatory requirements of the Falsified Medicines Directive (FMD).
As part of its strategic expansion into pharmaceutical products in recent years. Surfachem has broadened its portfolio to include APIs, pharmaceutical excipients, speciality polymers and film coatings and invested in customer services with a second to none comprehensive technical support tailored to customers’ and principals’ individual needs.
Richard Smith MD said: “Approval by the MHRA for APIs is part of our company strategy to be recognised as the first choice partner for customers and key principals.
“Operating across diverse sectors including pharmaceutical, household and personal care demands adherence to the highest standards and evidence that we will maintain them at all times. This approval emphasises the industry credibility we have accrued in over 30 years of trading.
“Customers recognize that we deliver the right product in the right quantity at the right time. Our continued investment in innovation with rigorous quality assurance and regulatory compliance makes us a partner of choice for many.”